Abstract This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Roland Meisel
Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis?
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center
Update of the decision-making algorithm on selecting transfusion-dependent β-thalassemic patients for gene therapy approaches: joint consensus report on behalf of EHA-specialized working group and EBMT hemoglobinopathies working party
Abstract β-thalassemia is a globally distributed hereditary red blood cell disorder. Up to now, clinical management of transfusion-dependent β-thalassemia (TDT) patients is still based on chronic transfusion combined with iron chelation therapy. Allogeneic hematopoietic cell transplantation potentially provides a cure, but few patients have an HLA-identical sibling, and optimal results are reported in patients ≤ 14 years.
HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee
|
By Esteban Arrieta-Bolaños, Marco Andreani, Dianne De Santis, Florent Malard, Neema P. Mayor, Rohtesh S Mehta, Roland Meisel, Simona Pagliuca, Effie Petersdorf, Simona Piemontese, Nicoletta Sacchi, Nicole Santoro, Jaime Sanz, Johannes Schetelig, Stephen Spellman, Francesco Onida, Isabel Sánchez-Ortega, Mohamad Mohty Verified, Ibrahim Yakoub-Agha, Katharina Fleischhauer, Annalisa Ruggeri
|
Nature
Verified
Abstract HLA compatibility has been a cornerstone for safe and successful allogeneic haematopoietic cell transplantation (HCT), with human leukocyte antigen (HLA)-mismatched transplants consistently associated with inferior survival. However, recent advances in typing technologies, supportive care, and novel graft-versus-host disease (GvHD) prophylaxes have prompted the revisiting of HLA mismatch relevance in contemporary HCT.
Excellent survival after allogeneic HSCT in screened SCID patients and donor type dependent naïve T cell reconstitution
To the Editor Severe combined immunodeficiency (SCID) is defined by profound numeric or functional T cell deficiency and, without treatment almost all patients die within the first year of life due to severe infections or immune dysregulation [1]. Early and sufficient T cell restoration, typically achieved by allogeneic hematopoietic stem cell transplantation (HSCT), is essential, while gene therapy or enzyme replacement are options for selected entities [2].
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group
Research ExplorerPublicationsHaematopoietic stem cell transplantation after reduced inten... Abstract Bibliographical data
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression - Bone Marrow Transplantation
Abstract We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged mainly to Pesaro risk class 1–2.
Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft - Bone Marrow Transplantation
To the Editor: Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood [1]. More than 90% of patients harbor mutations in PTPN11, KRAS, NRAS, CBL, or NF1. For most patients, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy, while relapse is the major cause of treatment failure recorded in about 35% of patients [2, 3].
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial | Leukemia
Abstract Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Roland
Contact Roland, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack